DexCom, Inc. (BVMF:D1EX34)
Brazil flag Brazil · Delayed Price · Currency is BRL
7.19
-0.26 (-3.49%)
At close: Mar 6, 2026

DexCom Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.

The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application.

It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.
Country United States
Founded 1999
Industry Medical Devices
Sector Healthcare
Employees 11,050
CEO Jacob Leach

Contact Details

Address:
6340 Sequence Drive
San Diego, California 92121
United States
Phone 858 200 0200
Website dexcom.com

Stock Details

Ticker Symbol D1EX34
Exchange Brazil Stock Exchange
Fiscal Year January - December
Reporting Currency USD
SIC Code 3845

Key Executives

Name Position
Jacob Steven Leach President, Chief Executive Officer and Director
Kevin Ronald Sayer Executive Chairman of the Board (Leave of Absence)
Jereme M. Sylvain CPA Executive Vice President, Chief Financial Officer and Chief Accounting Officer
Michael Jon Brown Executive Vice President and Chief Legal Officer
Sadie M. Stern Executive Vice President and Chief Human Resources Officer
Girish Naganathan Executive Vice President and Chief Technology Officer
Sean Christensen Vice President of Finance and Investor Relations
Matthew Dolan Executive Vice President of Strategy and Corporate Development
Donald M. Abbey Executive Vice President of Global Business Services, Regulatory, Medical and Clinical Affairs
Jon Coleman Executive Vice President and Chief Commercial Officer